Amazingly, antiangiogenic compounds showed a limited efficacy because they all bind on the Vascular Endothelial Growth Factor (VEGF) or the VEGF receptor and tumor cells can trigger different biological ways to have angiogenesis [11]. The gene discussed is VEGFA; the disease is neoplasm.